Full-Time

Director Program Management

Senior Director

Updated on 9/3/2026

Adicet Bio

Adicet Bio

51-200 employees

Off-the-shelf gamma delta T therapies

Compensation Overview

$231k - $319k/yr

+ Annual cash bonus + Equity + Employee Stock Purchase Plan + 4.5% 401(k) company match

Redwood City, CA, USA

Hybrid

At least three days onsite per week are required; Tuesday through Thursday are mandatory.

Bachelor's, PharmD, PhD

Category
Project & Program Management (1)
Required Skills
SharePoint
Risk Management

Get referred to Adicet Bio

See people who can refer or advise you

Requirements
  • A BA or BS degree is required.
  • At least 10 years of industry experience, including a minimum of 5 years of project management experience in a cross-functional pharmaceutical or biotechnology team environment.
  • Deep understanding of the drug development process.
  • Strong planning, organizational, and analytical skills with keen attention to detail.
  • Demonstrated ability to build trust and strengthen collaborative relationships across teams, sub-teams, and functions in a matrix environment.
  • Ability to drive program plans and timelines across multiple functional areas.
  • Proven success in goal setting, prioritization, and time management.
  • Experience using established project-management planning tools such as Microsoft Project or Smartsheet.
  • A proactive mindset with leadership, facilitation, teamwork, influence, management, and negotiation skills.
  • Ability to work independently in decision-making and resolution of program obstacles.
  • Excellent verbal and written communication skills.
Responsibilities
  • Create and drive integrated program timelines and Gantt charts for tracking activities and milestones based on clear dependencies and assumptions.
  • Collaborate with cross-functional leaders in planning, coordinating, and tracking cross-functional activities.
  • Maintain and communicate critical-path activities.
  • Partner with cross-functional leaders to optimize team effectiveness, team dynamics, and decision-making.
  • Facilitate team building, communication, meetings, meeting minutes, decision and action documentation, and follow-up on action items.
  • Proactively and independently identify and resolve program-team challenges.
  • Perform risk-management assessments and drive implementation of mitigation plans.
  • Drive information flow and communicate program status to stakeholders.
  • Create regular status reports covering milestones, status, issues, and decisions for senior management with input from the team.
  • Assist the Finance group in compiling and tracking the program budget in alignment with company goals and objectives.
  • Ensure, in partnership with functional managers, that assigned program resources are adequate and identify resource constraints.
  • Maintain effective oral and written communication within the program team and document communications.
  • Organize and maintain electronic platforms such as SharePoint and shared folders for reporting, archiving, and project documentation.
  • Build trusting relationships with the team and stakeholders to encourage collaboration.
  • Collaborate with cross-functional leaders to prepare and facilitate governance meetings.
  • Cultivate and maintain professional relationships with China-based stakeholders through structured communication and collaborative frameworks.
  • Organize lessons-learned sessions to evaluate project activities and apply prior experience.
  • Serve as a resource for other Program Managers as appropriate.
  • May manage other junior Program Management staff.
  • Contribute to the development of the Program Management Department by introducing tools and processes for continuous improvement.
Desired Qualifications
  • An advanced degree such as PharmD or PhD.
  • Experience in oncology and/or autoimmune diseases.
  • Cell therapy experience.
  • Project Management Professional certification.

Adicet Bio develops cancer immunotherapies using donor-derived, allogeneic gamma delta T cells that are engineered to target and kill cancer cells. The therapy uses off-the-shelf cells instead of a patient’s own cells, making treatment faster and potentially more readily available. The product works by introducing these modified T cells into a patient, where they seek out and destroy tumor cells. Adicet Bio differentiates itself by providing an immediately available, genetically modified immune cell therapy rather than patient-specific treatments, and by focusing on gamma delta T cells, which may offer targeted anti-tumor activity with a different safety and efficacy profile. The company aims to bring these therapies to patients through commercialization, licensing, and partnerships with healthcare providers and larger pharma companies, supported by ongoing research and development and strategic initiatives like the merger with resTORbio and a substantial funding round.

Company Size

51-200

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Get referred to Adicet Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 prula-cel topline data covers 22 SLE/LN patients, including 13 with 12-month follow-up.
  • Cash and investments were $118.2 million on June 30, 2026, funding into second half 2027.
  • ADI-212 filing remains planned for third quarter 2026, with enrollment targeted for fourth quarter 2026.

What critics are saying

  • July 2025 layoffs and lower headcount cut R&D, signaling brittle execution and thin operating capacity.
  • July 2026 CMO Julie Maltzman resigned; interim coverage increases trial and regulatory continuity risk.
  • Adicet generated no revenue in Q2 2026; one failed prula-cel readout threatens solvency and Nasdaq status.

What makes Adicet Bio unique

  • Adicet's gamma delta allogeneic CAR-T platform targets both autoimmune disease and solid tumors.
  • prula-cel uses outpatient dosing alignment from FDA in November 2025, lowering treatment complexity.
  • ADI-212 combines PSMA targeting, IL-12 armoring, and MED12 knockout for multi-mechanism solid-tumor attack.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
BioSpace
Jul 22nd, 2026
Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference.

Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference. July 22, 2026 | REDWOOD CITY, Calif.-(BUSINESS WIRE)-Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston. Details of the event are as follows: Date: Tuesday, August 11, 2026 Time: 10:30 a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com. Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ [email protected]

Adicet Bio
Jul 21st, 2026
Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference.

Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference. REDWOOD CITY, Calif.-(BUSINESS WIRE)-Jul. 21, 2026- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston. Details of the event are as follows: Date: Tuesday, August 11, 2026 Time: 10:30 a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit its website at https://www.adicetbio.com. Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ [email protected]

TipRanks
Jan 7th, 2026
Adicet Bio doubles prula-cel Phase 1 enrolment, extends cash runway to 2027 with $75M raise

Adicet Bio has expanded enrollment in its Phase 1 prula-cel programme for autoimmune diseases to over 20 patients as of 31 December 2025, more than doubling since October. All seven autoimmune cohorts are now actively enrolling, including the first ANCA-associated vasculitis patient. The company has secured FDA alignment for outpatient dosing of lupus nephritis and systemic lupus erythematosus patients. Adicet is also advancing ADI-212 for metastatic castration-resistant prostate cancer, targeting a regulatory filing in the first half of 2026. An October 2025 equity raise of approximately $74.8 million has extended the company's cash runway into the second half of 2027. Multiple clinical data updates are planned throughout 2026 as Adicet works towards a pivotal trial design.

Investing.com
Oct 7th, 2025
Adicet Bio $80M Stock Offering Announced

Adicet Bio (NASDAQ:ACET) announced an $80 million stock offering, pricing 70,001,000 shares at $1 each and pre-funded warrants for 10 million shares at $0.9999. The offering, expected to close by October 8, 2025, aims to bolster finances amid rapid cash burn. Jefferies and Guggenheim Securities are joint book-running managers. Adicet also reported positive results from its ADI-001 trial and halted ADI-270 development, reducing its workforce by 30% to extend cash reserves into Q4 2026.

BioProcess International
Aug 13th, 2025
Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies

Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies.